P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000969552.85501.cf |
| _version_ | 1797280215561404416 |
|---|---|
| author | Jorge Cortes Michael Deininger Elza Lomaia Beatriz Moiraghi Soledad Undurraga Carolina Pavlovsky Charles Chuah Tomasz Sacha Jeffrey H. Lipton James Mccloskey Philippe Rousselot Gianantonio Rosti Hugues de Lavallade Christine Rojas Anna Turkina Moshe Talpaz Michael Mauro Vickie Lu Alexander Vorog Jane Apperley |
| author_facet | Jorge Cortes Michael Deininger Elza Lomaia Beatriz Moiraghi Soledad Undurraga Carolina Pavlovsky Charles Chuah Tomasz Sacha Jeffrey H. Lipton James Mccloskey Philippe Rousselot Gianantonio Rosti Hugues de Lavallade Christine Rojas Anna Turkina Moshe Talpaz Michael Mauro Vickie Lu Alexander Vorog Jane Apperley |
| author_sort | Jorge Cortes |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:37:55Z |
| format | Article |
| id | doaj.art-f0b8d7a160ec4ce1b84d936813ace846 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:37:55Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-f0b8d7a160ec4ce1b84d936813ace8462024-03-03T09:43:11ZengWileyHemaSphere2572-92412023-08-017e85501cf10.1097/01.HS9.0000969552.85501.cf202308003-00562P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIBJorge Cortes0Michael Deininger1Elza Lomaia2Beatriz Moiraghi3Soledad Undurraga4Carolina Pavlovsky5Charles Chuah6Tomasz Sacha7Jeffrey H. Lipton8James Mccloskey9Philippe Rousselot10Gianantonio Rosti11Hugues de Lavallade12Christine Rojas13Anna Turkina14Moshe Talpaz15Michael Mauro16Vickie Lu17Alexander Vorog18Jane Apperley191 Georgia Cancer Center2 Versiti Blood Research Institute, Medical College of Wisconsin, Milwaukee, WI3 Almazov National Medical Research Centre, St. Petersburg, Russia4 Hospital Jose Maria Ramos Mejia, Buenos Aires, Argentina5 Hospital del Salvador, Santiago, Chile6 Fundaleu, Buenos Aires, Argentina7 Singapore General Hospital, Duke-NUS Medical School, Singapore, Singapore8 Jagiellonian University Hospital in Krakow, Krakow, Poland9 Princess Margaret Cancer Centre, Toronto, Ontario, Canada10 The John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, United States11 Centre Hospitalier de Versailles University de Versailles Saint-Quentin-en-Yvelines, Paris, France12 IRST/IRCCS “Dino Amadori”, Meldola (FC), Italy13 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom14 Centro de Investigaciones Clinicas Vina del Mar, Valparaíso, Chile15 National Medical Research Center for Hematology, Moscow, Russia16 Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, United States17 Memorial Sloan Kettering, New York, New York, NY, United States18 Takeda Development Center Americas, Inc., Lexington, MA, United States18 Takeda Development Center Americas, Inc., Lexington, MA, United States19 Imperial College London, London, United Kingdomhttp://journals.lww.com/10.1097/01.HS9.0000969552.85501.cf |
| spellingShingle | Jorge Cortes Michael Deininger Elza Lomaia Beatriz Moiraghi Soledad Undurraga Carolina Pavlovsky Charles Chuah Tomasz Sacha Jeffrey H. Lipton James Mccloskey Philippe Rousselot Gianantonio Rosti Hugues de Lavallade Christine Rojas Anna Turkina Moshe Talpaz Michael Mauro Vickie Lu Alexander Vorog Jane Apperley P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB HemaSphere |
| title | P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB |
| title_full | P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB |
| title_fullStr | P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB |
| title_full_unstemmed | P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB |
| title_short | P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB |
| title_sort | p662 post hoc analysis of patient responses by t315i mutation status from the 3 year update of the optic trial a dose optimization study of 3 starting doses of ponatinib |
| url | http://journals.lww.com/10.1097/01.HS9.0000969552.85501.cf |
| work_keys_str_mv | AT jorgecortes p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT michaeldeininger p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT elzalomaia p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT beatrizmoiraghi p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT soledadundurraga p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT carolinapavlovsky p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT charleschuah p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT tomaszsacha p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT jeffreyhlipton p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT jamesmccloskey p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT philipperousselot p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT gianantoniorosti p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT huguesdelavallade p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT christinerojas p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT annaturkina p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT moshetalpaz p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT michaelmauro p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT vickielu p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT alexandervorog p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib AT janeapperley p662posthocanalysisofpatientresponsesbyt315imutationstatusfromthe3yearupdateoftheoptictrialadoseoptimizationstudyof3startingdosesofponatinib |